Menu

Palantir Technologies Inc. PLTR

Full chart Compare
Set alert

Price alert · PLTR

All alert types
160.38 USD +5.39 (+3.48%)

At closeNov 9, 2026, 6:00 AM EST

161.00 +0.62 +0.39%

Pre-market · Nov 9, 6:00 AM ET

157.24 Day range 163.97
106.37 52-week range 212.94
YTD
-9.77%
1 year
-9.86%

Discussion (3514)

Sign in to join the discussion

Alan Jack PLTR 15 hours ago #1

Fear held me back from investing for a very long time. I was afraid of losing money, making wrong decisions, and stepping into something I didn't fully understand. But eventually, I realized that staying afraid would only keep me stuck in the same financial position. I decided to take a step forward and learn. That decision changed everything. Through education, patience, and smart investment planning, I began earning $8,200 daily and seeing positive results. Not only did I grow financially, but I also grew mentally by the guidance of a mentor William Jones more and his confident in handling opportunities and risks. You can message him on Telegram for more info 📲 https://t.me/williams615

Zeev Bovan PLTR 5 days ago #2

Pslantir will become a1000$ plus stock but it will take along nerve wrecking time, like an over inflated balloon it will loose air and gain air till the company generate enough profits to justify the insane pe.

NeMo PLTR 6 days ago #4

With over 150 PEvit was bound to crushed

Almighty PLTR 6 days ago #5

Dems will be all over this company looking into its financials and dealings with the government.

StockMaster PLTR 6 days ago #6

$PLTR...VERY solid earnings... but right now, no matter what you deliver, the "shit Street" is never satisfied.

Zeev Bovan PLTR 2 weeks ago #9

$TARA

Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support
Protara Therapeutics
October 15, 2026 08:00 ET

Zeev Bovan PLTR 3 weeks ago #10

Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support
Protara Therapeutics
October 15, 2026 08:00 ET

$TARA